In this @jamainternalmed.com editorial, CP3's @timandersonmd.bsky.social highlights overuse of PPIs and a large trial showing deprescribing works best when clinicians + patients are both engaged, doubling dose reductions vs usual care.
jamanetwork.com/journals/jam...
Medicaid study (2016–2020) shows progress—MOUD use rose across all racial/ethnic groups—but major gaps persist. Disparities are largest for buprenorphine. Findings highlight the need for targeted policies to expand equitable access.
www.jsatjournal.com/article/S294...
At CP3, we make our research effective to real-world issues, and that often means collaborating with local partners to strengthen our impact. We've been recognized on a list of others at Pitt doing the same!
www.externalrelations.pitt.edu/public-impac...
PCPs often initiate opioid deprescribing talks w/older adults, but approaches vary by risk. Confidence ⬇️when OUD suspected, & naloxone is underused. Clinicians need more tools to navigate deprescribing conversations.
More @agsjournal.bsky.social:
agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
Join us in congratulating our Noah Feder, who was accepted into the competitive Master of Science in Clinical Research
Clinical Scientist Training Program offered to University of Pittsburgh School of Medicine students!
In Tanzania & Bangladesh, biosimilar insulin glargine can be cost-effective vs NPH for youth w/T1D—but it hinges on price & delivery device. Cartridges worked in Bangladesh; vials could work in both if💲right. Fewer nighttime hypoglycemia events drive the benefit.
journals.plos.org/plosone/arti...
Study of VA data found 67% of outpatient drug supply disruptions led to shortages. Orders spiked sharply before shortages while fills dropped—suggesting ordering surges may be an early warning sign of impending drug shortages.
www.sciencedirect.com/science/arti...
CP3's Dr. Katie Suda & @pharmacy.utoronto.ca @mina-t.bsky.social recently shared their drug shortages work to the 10th Annual PITT OHIO 2026 Supply Chain Management Symposium, in a presentation titled "The Pharmaceutical Supply Chain in the Real World: From Data to Policy Solutions."
CP3's @timandersonmd.bsky.social contributed to the new @americanheart.bsky.social guidelines to address evaluation, management, & monitoring of individuals with dyslipidemias.
Read the guidelines here: www.ahajournals.org/doi/10.1161/...
Pharmacy owners/managers, pharmacists, & techs: Share how Medicare Part D changes under the IRA are affecting your pharmacy & patients. Participate a 60-min virtual interview ($100 honorarium) with researchers from RAND/Vanderbilt/CP3. Details below.
Sign up: answer.rand.org/IRA
The Incidental Economist explores how to pay for high-cost #genetherapies, including “rev pay” models that spread costs over time to address large upfront prices, payer risk, & patient mobility. The piece cites CP3 research on financing for gene therapies.
theincidentaleconomist.com/wordpress/ge...
New @jamainternalmed.com study led by CP3’s @timandersonmd.bsky.social: a virtual, team-based program (pharmacist tapering + mindfulness CBT) helped older adults reduce benzodiazepines by ~60%. Feasible, acceptable, and ready for multi-site testing.
link.springer.com/article/10.1...
Dental visits jump after starting medications for opioid use disorder (MOUD)—across methadone, buprenorphine, and naltrexone. Likely reflects increased health-seeking, not drug harm. Studies on dental risks should account for this behavior shift.
journals.lww.com/journaladdic...
Join us May 12 at noon for a seminar from CP3/Pitt Pharmacy Visiting Scholar Adam Bress. All are welcome!
Register: calendar.pitt.edu/event/semina...
@jamainternalmed.com editorial highlights early impact of 2024 IRA Part D reforms: cost-related💊nonadherence fell among Medicare beneficiaries but rose among commercially insured adults. Gains are promising, but affordability challenges remain.
jamanetwork.com/journals/jam...
🆕@statnews.com article highlights shifts in CVD prevention guidelines, including considering statins as early as age 30 & using updated risk tools. CP3’s @timandersonmd.bsky.social notes focus on balancing long-term benefits w/risks & IDing high-risk pts earlier.
www.statnews.com/2026/03/13/h...
🆕study of Medicare beneficiaries w/incident osteoarthritis found hypertension didn't influence initial analgesic choice. Intra-articular injections & oral NSAIDs most common; topical NSAID use⬆️, opioid combos⬇️. Co-authored by CP3’s @jennylociganic.bsky.social.
pubmed.ncbi.nlm.nih.gov/41833532/
🆕paper introduces DF-learner, a distributed learning approach to estimate heterogeneous tx effects across multiple data sites w/o sharing individual-level data. Applied to MOUD using PA Medicaid data, it enables privacy-preserving, efficient multi-site analysis.
academic.oup.com/biometrics/a...
🆕study in @plosone.org finds many US medical school conflict-of-interest policies remain less stringent than expert recommendations, highlighting need for stronger policies & enforcement to protect medical education. Co-authored by CP3’s @timandersonmd.bsky.social.
journals.plos.org/plosone/arti...
🆕research with CP3 collaborators develops an ML model using EHR data to predict 3-month risk of opioid use disorder after opioid initiation. The model showed strong performance and could help health systems identify high-risk patients earlier and target prevention.
www.jmir.org/2026/1/e79482/
People with neurogenic bladder may experience substantial QoL impacts from UTIs, & patient-centered interventions may be needed to decrease the impact of UTIs. Co-authored by CP3's Dr. Katie Suda.
Read more: onlinelibrary.wiley.com/doi/10.1002/...
🆕study with CP3’s @walidgellad.bsky.social & Noah Feder, finds MS drug list prices keep climbing, but net prices diverge.
Analysis began when lead author Dr. Dan Hartung was CP3 visiting scholar.
Read more:
www.neurology.org/doi/10.1212/...
🆕editorial in @jamainternalmed.com by CP3’s @timandersonmd.bsky.social & colleagues examines when statins should be used for prevention of ASCVD. As risk calculators evolve, debate continues over lowering treatment thresholds.
jamanetwork.com/journals/jam...
In @jamainternalmed.com, CP3's @timandersonmd.bsky.social & coauthors describe strategies for medication safety for older adults in the emergency department.
jamanetwork.com/journals/jam...
New @cidrap.bsky.social article offers tips to avoid inappropriate dental antibiotic use to curb resistance and patient harm. CP3’s Katie Suda was interviewed, highlighting stewardship strategies for dentists to choose when antibiotics are truly needed.
www.cidrap.umn.edu/antimicrobia...
New @cidrap.bsky.social article shows dentists still write millions of antibiotic prescriptions annually, many of which may be unnecessary. CP3’s Dr. Katie Suda was consulted on the need for improved stewardship in dental settings to curb overuse and resistance.
www.cidrap.umn.edu/antimicrobia...
🆕study co-authored by CP3’s @timandersonmd.bsky.social finds 9% of US adults 30–59 have ⬆️30-year ASCVD risk despite⬇️10-year risk. Many have uncontrolled risk factors, & expanding statins could benefit ~2.5M more adults. Long-term risk may reshape prevention.
pmc.ncbi.nlm.nih.gov/articles/PMC...
🆕study led by CP3’s @bryantshuey.bsky.social finds employer-mandated switches to high-deductible plans were linked to delays in OUD-related high-acuity care and 37% fewer high-acuity care days, raising concerns about cost-sharing barriers to timely treatment.
journals.lww.com/journaladdic...
The agenda for @cpddorg.bsky.social #cpdd26 is out, and we can't wait to join our colleagues from @brownpublichealth.bsky.social to share lessons learned from implementing #machinelearning driven #overdose prevention interventions!
cpdd.societyconference.com/conf/#sessio...
New @plosone.org study finds long-term opioid therapy is linked to higher risk of infection-related dental outcomes in a national VA cohort, underscoring oral health risks in chronic opioid users. CP3's Dr. Katie Suda is a co-author.
journals.plos.org/plosone/arti...